Key Takeaways
-
Most probiotics fit into three main categories: Lactobacillus–Bifidobacterium blends, Saccharomyces boulardii, and soil-based probiotics.
-
Probiotic strains get the most attention, but their importance is often overstated. In practice, the species and broader probiotic category are usually more useful when choosing a product.
-
Lactobacillus–Bifidobacterium probiotics have the broadest research base, especially for irritable bowel syndrome (IBS), bloating, abdominal pain, irregular bowel habits, and general digestive support.
-
Saccharomyces boulardii is especially well studied for diarrhea and antibiotic-related gut disruption, including antibiotic-associated diarrhea and certain intestinal infections.
-
Soil-based probiotics have been studied most for digestive symptoms like bloating, abdominal pain, diarrhea, constipation, and stool consistency, particularly in people with IBS.
✓ Reviewed by our Scientific Review Board · All claims supported by peer-reviewed research · Last updated April 2026
There are hundreds of probiotic species and strains, which can make choosing one feel much more complicated than it needs to be.
Clinically, I find it much more useful to organize probiotics into three broad categories:
- Lactobacillus and Bifidobacterium blends
- Saccharomyces boulardii
- Soil-based, or Bacillus, probiotics
Each category contains different microorganisms and has slightly different strengths. Understanding these three groups can make it much easier to decide which probiotic makes the most sense for you.
Let’s look at how they differ, what the research tells us about each, and whether you really need all three.
Types of Probiotics: The Three Main Categories Explained
Probiotics can be described at several levels: type (genus), species, and strain. For example, Lactobacillus is a genus, Lactobacillus rhamnosus is a species, and an individual strain (e.g., Lactobacillus rhamnosus GG) is a more specific version within that species. For practical use, I also group probiotics into broader categories or types based on the kinds of microorganisms they contain.
Other probiotic types exist beyond these three, including Streptococcus, Enterococcus, and newer organisms like Akkermansia muciniphila. Research on these is still developing, and they aren’t yet part of standard clinical use the way the three categories below are. For most people, these three categories cover what the evidence supports and what we use in practice.
You’ll often see a lot of emphasis placed on choosing a specific probiotic strain for a specific symptom. I believe that level of strain specificity is overstated and can make probiotic selection unnecessarily complicated. Clinically, I find it more useful to focus on probiotic categories and species, because the evidence tends to show overlap in benefits within these groups.
Type 1: Lactobacillus and Bifidobacterium Probiotics
What it is: Lactobacillus and Bifidobacterium probiotics are the most widely studied category of probiotics and the type most people are familiar with, often seen in probiotic foods like yogurt.
These products usually combine several species from the Lactobacillus and Bifidobacterium families. Lactobacillus species are typically found throughout the digestive tract, while Bifidobacterium species are more commonly concentrated in the large intestine.
What it does: These probiotics generally do not permanently colonize the gut. Instead, they appear to provide benefits while they pass through, helping support the gut environment, immune function, and the balance of the microbiome.
Research on Lactobacillus and Bifidobacterium blends is especially strong for digestive symptoms. They have been studied for:
- Immunity and microbiome support 1
- Anxiety 2
- Inflammatory bowel disease (IBD) 3
- Allergic and inflammatory conditions 4
- Vaginal and urinary tract infections 5
- Bacterial overgrowth 6
Because this category has the broadest research base, it is often a practical starting point for someone who is new to probiotics or looking for general digestive support.
Common species include:
- Lactobacillus acidophilus
- Lactobacillus rhamnosus
- Lactobacillus plantarum
- Lactobacillus reuteri
- Bifidobacterium longum
- Bifidobacterium infantis
- Bifidobacterium lactis
- Bifidobacterium bifidum
Type 2: Saccharomyces boulardii
What it is: Saccharomyces boulardii, or S. boulardii, is a beneficial yeast rather than a bacterium. That makes it distinct from Lactobacillus, Bifidobacterium, and most other probiotics. Like many probiotics, S. boulardii does not permanently colonize the gut. It passes through the digestive tract while exerting its effects.
What it does: S. boulardii appears to be especially useful for supporting the gut during disruptions from antibiotics, infections, and other forms of dysbiosis. Research suggests it may help reduce diarrhea, support recovery from certain intestinal infections, and improve the balance of the gut microbiome 7 8.
S. boulardii has been used successfully in research for:
- Irritable bowel syndrome (IBS) 9
- Diarrhea 10
- C. difficile infections and related diarrhea 7 11
- Crohn’s disease 7
- Inflammatory bowel disease 12
- Parasitic infections with Giardia 13 and Blastocystis hominis 14
- Increasing clearance of H. pylori infection 15 16
Because S. boulardii is a yeast, antibiotics that target bacteria generally do not kill it. That makes it a particularly useful probiotic to consider during or after antibiotic treatment.
Unlike the other two categories, S. boulardii isn’t a genus with multiple species. It’s a single, well-defined species, most often labeled as Saccharomyces boulardii or Saccharomyces cerevisiae var. boulardii on product labels.
Type 3: Soil-Based Probiotics
What it is: Soil-based probiotics are usually made from Bacillus species, including Bacillus coagulans and Bacillus subtilis. Unlike the other probiotic types, this category of probiotic can colonize your gut 17. They’re also called spore-forming probiotics because these bacteria can enter a dormant spore state. That spore structure makes them especially resilient. They can better withstand heat, stomach acid, and other harsh conditions as they move through the digestive tract.
What it does: A number of soil-based species show health benefits, including Bacillus coagulans and Bacillus subtilis 18.
Research shows soil-based probiotics help:
- Improve diarrhea, abdominal pain, bloating, and stool consistency in people with IBS 19 20
- Reduce acute diarrhea 21
- Improve constipation 22 23
- Decrease leaky gut 24
- Decrease adverse events from antibiotics 25
- Decrease inflammation 18 26
- Decrease respiratory tract infections 27
Common species include:
- Bacillus clausii
- Bacillus coagulans
- Bacillus subtilis
What the Research Shows
A 2021 systematic review and meta-analysis pooled results from 42 randomized controlled trials involving nearly 3,900 people with IBS to determine which probiotics have solid evidence behind them [9]. Only a handful of strains showed a significant reduction in abdominal pain, and they came from different categories: a soil-based strain (Bacillus coagulans MTCC5260), a Lactobacillus strain (L. plantarum 299v), and Saccharomyces boulardii. Most other individual strains tested showed no meaningful benefit.
EClinicalMedicine. 2021 Nov; 41 101154
Which Type of Probiotic Should You Take?
Each of the three probiotic categories has value on its own, and there are situations where starting with one category makes sense.
In the clinic, though, we often use all three categories together. This is the Probiotic Triple Therapy approach. The idea is simple: Lactobacillus–Bifidobacterium blends, Saccharomyces boulardii, and soil-based probiotics each bring something slightly different to the table. Combining them gives you broader probiotic coverage than relying on a single category alone.
| Probiotic Type | Best Known For | May Be a Good Fit If… |
|---|---|---|
Lactobacillus + Bifidobacterium |
Broad digestive support and the largest research base |
You’re new to probiotics or want a good general starting point |
Saccharomyces boulardii |
Supporting the gut during antibiotics, diarrhea, and certain infections |
You’re taking antibiotics, recently took them, or tend toward diarrhea |
Soil-based probiotics |
Digestive support from resilient, spore-forming bacteria |
You want another bacterial option or haven’t gotten enough benefit from traditional probiotics |
The Triple Therapy approach also helps avoid getting overly focused on finding one “perfect” strain for one specific symptom. The three probiotic categories have overlapping benefits, and using them together may give you a more complete effect.
If you’re still unsure and would like help selecting a probiotic, take my Gut Health Quiz.
CLINICAL OBSERVATION
In my clinical experience, most patients tolerate starting all three categories together without issue. But for patients who are sensitive or reactive, I've found it works better to introduce one category at a time, usually starting with a Lactobacillus–Bifidobacterium blend, and layer in the others as tolerated. This lets us pinpoint which category, if any, is causing a reaction, rather than guessing after the fact.
— Dr. Michael Ruscio, DC
Liked this article? Get weekly gut health insights.
Join 40,000+ readers who get evidence-based health tips — no spam, no fluff.
By subscribing you agree to our Privacy Policy. Unsubscribe anytime.
FAQs About Types of Probiotics
Soil-based probiotics aren’t inherently better. They’re simply a different category.
Their spore-forming structure makes them especially resilient, and they have promising research for IBS and other digestive symptoms. But Lactobacillus–Bifidobacterium blends and S. boulardii also have strong evidence.
The better question is whether one category is enough for you or whether you may benefit from combining categories.
Not always. Someone who is new to probiotics or has milder symptoms may do well starting with one category.
In the clinic, though, we often use all three categories together when symptoms are more persistent or when someone has already tried a probiotic without enough improvement. This broader approach is what we call Triple Therapy.
Strain specificity is often overstated in discussions about probiotics.
The research does not suggest that you need to match one exact probiotic strain to one exact symptom in order to get a benefit. In practice, I find it more useful to think in terms of species and broader probiotic categories. For example, instead of searching for one particular strain of Lactobacillus, focus on whether you’re using a well-formulated Lactobacillus–Bifidobacterium blend, Saccharomyces boulardii, a soil-based probiotic, or a combination of these categories.
Getting overly focused on strains can make probiotics seem much more complicated than they need to be and may actually make it harder to choose an effective product.
The Bottom Line
Most probiotics fall into one of three categories: Lactobacillus–Bifidobacterium blends, Saccharomyces boulardii, and soil-based probiotics. Each has its own research base and its own strengths, so the category matters more than chasing a specific strain.
If you’re new to probiotics or want general digestive support, a Lactobacillus–Bifidobacterium blend is a reasonable place to start. If you’re on antibiotics or dealing with diarrhea, Saccharomyces boulardii has the most relevant evidence. If you’ve tried a probiotic before without enough improvement, a soil-based option or a combination of categories may fill in the gap.
For more persistent symptoms, we typically use all three together, an approach we call Triple Therapy, since the categories tend to cover different parts of the picture rather than duplicating each other.
If you’re not sure where to start, you can book a consultation with our clinic if your symptoms haven’t responded to probiotics on their own.
Continue Reading
➕ References
- Liu Y, Wang J, Wu C. Modulation of Gut Microbiota and Immune System by Probiotics, Pre-biotics, and Post-biotics. Front Nutr. 2021;8:634897. DOI: 10.3389/fnut.2021.634897. PMID: 35047537. PMCID: PMC8761849.
- Kane L, Kinzel J. The effects of probiotics on mood and emotion. JAAPA. 2018 May;31(5):1–3. DOI: 10.1097/01.JAA.0000532122.07789.f0. PMID: 29698377.
- Amer M, Nadeem M, Nazir SUR, Fakhar M, Abid F, Ain Q-U, et al. Probiotics and their use in inflammatory bowel disease. Altern Ther Health Med. 2018 May;24(3):16–23. PMID: 29135456.
- Dhama K, Latheef SK, Munjal AK, Khandia R, Samad HA, Iqbal HMN, et al. Probiotics in Curing Allergic and Inflammatory Conditions – Research Progress and Futuristic Vision. Recent Pat Inflamm Allergy Drug Discov. 2017;10(2):105–18. DOI: 10.2174/1872213X10666161226162229. PMID: 28029082.
- Hanson L, VandeVusse L, Jermé M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: A systematic review. J Midwifery Womens Health. 2016 May;61(3):339–55. DOI: 10.1111/jmwh.12472. PMID: 27218592.
- Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017 Apr;51(4):300–11. DOI: 10.1097/MCG.0000000000000814. PMID: 28267052.
- McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202–22. PMID: 20458757. PMCID: PMC2868213.
- Ianiro G, Bruno G, Lopetuso L, Beghella FB, Laterza L, D’Aversa F, et al. Role of yeasts in healthy and impaired gut microbiota: the gut mycome. Curr Pharm Des. 2014;20(28):4565–9. DOI: 10.2174/13816128113196660723. PMID: 24180411.
- McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021 Nov;41:101154. DOI: 10.1016/j.eclinm.2021.101154. PMID: 34712929. PMCID: PMC8529205.
- McFarland LV, Goh S. Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: A systematic review and meta-analysis. Travel Med Infect Dis. 2019;27:11–9. DOI: 10.1016/j.tmaid.2018.09.007. PMID: 30278238.
- Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, et al. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):495–506. DOI: 10.1097/MPG.0000000000001081. PMID: 26756877.
- Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. J Cell Physiol. 2018 Mar;233(3):2091–103. DOI: 10.1002/jcp.25911. PMID: 28294322.
- Besirbellioglu BA, Ulcay A, Can M, Erdem H, Tanyuksel M, Avci IY, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6–7):479–81. DOI: 10.1080/00365540600561769. PMID: 16798698.
- Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011 Mar;108(3):541–5. DOI: 10.1007/s00436-010-2095-4. PMID: 20922415.
- Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015 Jun;41(12):1237–45. DOI: 10.1111/apt.13214. PMID: 25898944.
- Feng J-R, Wang F, Qiu X, McFarland LV, Chen P-F, Zhou R, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017 Oct;73(10):1199–208. DOI: 10.1007/s00228-017-2291-6. PMID: 28681177.
- Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Secretome of Intestinal Bacilli: A Natural Guard against Pathologies. Front Microbiol. 2017 Sep 1;8:1666. DOI: 10.3389/fmicb.2017.01666. PMID: 28919884. PMCID: PMC5586196.
- Nyangale EP, Farmer S, Cash HA, Keller D, Chernoff D, Gibson GR. Bacillus coagulans GBI-30, 6086 Modulates Faecalibacterium prausnitzii in Older Men and Women. J Nutr. 2015 Jul;145(7):1446–52. DOI: 10.3945/jn.114.199802. PMID: 25948780.
- Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014;7(3):156–63. PMID: 25120896. PMCID: PMC4129566.
- AbdelQadir YH, Nabhan AI, Althawadi YJ, Belal MM, Feiter YY, Madian MS, et al. Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials. Gastroenterology & Endoscopy. 2024 Jan;2(1):7–18. DOI: 10.1016/j.gande.2023.11.001.
- Sudha MR, Bhonagiri S, Kumar MA. Efficacy of Bacillus clausii strain UBBC-07 in the treatment of patients suffering from acute diarrhoea. Benef Microbes. 2013 Jun 1;4(2):211–6. DOI: 10.3920/BM2012.0034. PMID: 23443952.
- Kang S, Park MY, Brooks I, Lee J, Kim SH, Kim JY, et al. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial. Food Res Int. 2021 Aug;146:110428. DOI: 10.1016/j.foodres.2021.110428. PMID: 34119240.
- Madempudi RS, Neelamraju J, Ahire JJ, Gupta SK, Shukla VK. Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2020 Jun;12(2):335–42. DOI: 10.1007/s12602-019-09542-9. PMID: 30911991.
- McFarlin BK, Henning AL, Bowman EM, Gary MA, Carbajal KM. Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):117–26. DOI: 10.4291/wjgp.v8.i3.117. PMID: 28868181. PMCID: PMC5561432.
- Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181–8. DOI: 10.1111/j.1365-2036.2004.02274.x. PMID: 15569121.
- Du S-X, Jia Y-R, Ren S-Q, Gong X-J, Tang H, Wan-Shui W, et al. The protective effects of Bacillus licheniformis preparation on gastrointestinal disorders and inflammation induced by radiotherapy in pediatric patients with central nervous system tumor. Adv Med Sci. 2018 Mar;63(1):134–9. DOI: 10.1016/j.advms.2017.09.005. PMID: 29120854.
- Anaya-Loyola MA, Enciso-Moreno JA, López-Ramos JE, García-Marín G, Orozco Álvarez MY, Vega-García AM, et al. Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Res Int. 2019 Nov;125:108567. DOI: 10.1016/j.foodres.2019.108567. PMID: 31554075.